VRAX - Virax Biolabs Group Ltd


0.2145
0.008   3.497%

Share volume: 72,284
Last Updated: 03-06-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances: -0.03%

PREVIOUS CLOSE
CHG
CHG%

$0.21
0.01
0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
8%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 20%
Performance
5 Days
2.63%
1 Month
-6.90%
3 Months
-54.28%
6 Months
-63.29%
1 Year
-84.29%
2 Year
-75.34%
Key data
Stock price
$0.21
P/E Ratio 
0.00
DAY RANGE
$0.20 - $0.22
EPS 
N/A
52 WEEK RANGE
$0.19 - $1.58
52 WEEK CHANGE
-$84.29
MARKET CAP 
15.066 M
YIELD 
N/A
SHARES OUTSTANDING 
3.233 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
2.82
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$176,292
AVERAGE 30 VOLUME 
$214,095
Company detail
CEO: James Foster
Region: US
Website: viraxbiolabs.com
Employees: 5
IPO year: 2022
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

Virax Cayman is a holding company incorporated as an exempted company under the laws of the Cayman Islands. As a holding company with no material operations of our own, Virax Cayman conducts our operations through its operating subsidiaries in Singapore, Hong Kong, China and British Virgin Islands and has been operating since 2013. Our principal executive office is located at 30 Broadwick Street London, W1F 8LX, United Kingdom. Our telephone number is +44 020 7788 7414. Our registered office in the Cayman Islands is located at the office of Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands. Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY.

Recent news